首页 >  > 


時間:2022-08-15 來源:本站 點擊:258次

Domestic adventure "Schemes in Antiques" stays atop Chinese box office******

BEIJING, Dec. 7 (Xinhua) -- Domestic adventure movie "Schemes in Antiques" on Monday continued to lead the Chinese mainland box office chart on its fourth day of screening, data from the China Movie Data Information Network showed Tuesday.。

Adapted from a novel of the same name, the movie tells a story of a series of adventures of the main characters to find out the truth surrounding a Buddha head from the Tang Dynasty (618-907). It raked in about 21.04 million yuan (about 3.3 million U.S. dollars) on Monday.。

The domestic comedy-suspense film "Be Somebody" ranked second on the box office chart, generating around 9.68 million yuan on Monday.。

It was followed by a domestic romance "Your World, Without Me," with daily revenue of around 1.74 million yuan. Enditem。

荣耀Play5 活力版发布:1799元起的66W快充手机******

  10月25日晚,荣耀在线上发布了荣耀Play5 活力版,主打2000元以内充电体验最佳、屏占比最高手机。

  荣耀Play5 活力版搭载4300mAh大电池,支持66W超级快充,15分钟可充电50%。电池内部结构采用单电芯双回路快充方案,容量等效增加10%,电池续航等效提升5%

  荣耀Play5 活力版正面采用了6.67英寸超窄边全视屏设计,屏幕左右黑边仅1.05mm,比业界普遍的2mm左右边框缩窄了一半,屏占比高达94.4%。这块屏幕支持120Hz智能动态帧率、DCI-P3色域、五重护眼等特性。

  荣耀Play5 活力版背面采用直边中框+3D曲面后盖设计,配色方面有极光蓝、幻夜黑可选。后摄采用居中矩阵式排布,规格为6400万主摄+200万景深。

  荣耀Play5 活力版全系8GB+2GB运存,支持智慧运存扩展技术,8G运存的基础上,可从存储空间中分出2GB空间,后台应用会被压缩流入硬盘扩展区暂存,应用被使用时,再解压流入前台。最终在硬件不变的情况下,实现额外2GB内存扩展,提升App冷启动速度,提升硬件后台保活率。

  荣耀Play5 活力版搭载天玑900 5G芯片,8+128GB售价1799元,8+256GB售价1999元。

【彩神-Welcome👉👉十年信誉大平台,点击进入👉👉 打造国内最专业最具信赖的彩票平台,为您提供彩神-Welcome用户登录全网最精准计划软件,APP下载登陆,强大的竞彩网上推荐!!】

Pfizer says COVID******

Pfizer said on Friday that a clinical trial of its pill to treat COVID-19 had shown it is highly effective, hailing it as a big step toward ending the pandemic.。

A simple pill to treat the coronavirus at home has been sought since the start of the global health crisis. So far all treatments have been either intravenous or vaccine shots.。

Pfizer's is the second anti-COVID pill after that of Merck, which is actually an influenza medicine rebranded to fight the coronavirus. Pfizer's has been created specifically to fight COVID-19.。

The Pfizer drug called Paxlovid achieved an 89 percent reduction in risk of hospitalization or death among adult patients with COVID-19 who are at high risk of progressing to severe illness, the US company said.。

The results from the middle-to-late stage clinical trial were so strong that Pfizer will stop recruiting new people for the trial, it said.。

Pfizer will submit the data to the Food and Drug Administration as soon as possible as part of its "rolling submission" for Emergency Use Authorization.。

"Today's news is a real game-changer in the global efforts to halt the devastation of this pandemic," said Pfizer CEO Albert Bourla.。

"These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients' lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of 10 hospitalizations," he added.。

Bourla told CNN he hopes the company can submit its authorization request before the Thanksgiving holiday, which this year falls on November 25.。

President Joe Biden said in remarks at the White House that the government has already secured millions of doses of the new medication.。

He said the pill "would be another tool in our toolbox to protect people from the worst outcomes of COVID-19."

The main analysis of the Pfizer pill data looked at numbers from 1,219 adults in North and South America, Europe, Africa and Asia.。

In the days immediately after symptoms appeared, some of them were given the experimental drug and others got a placebo – for five days, every 12 hours.。

Ten people who took the placebo died, while among those who got the Pfizer medication, none did.。

The search for a pill。

Several companies are working on so-called oral antivirals, which would mimic what the drug Tamiflu does for influenza and prevent the disease from progressing to severe.。

Britain on Thursday became the first country to approve an anti-COVID pill, as it greenlit the use of Merck's antiviral drug called molnupiravir to treat patients suffering from mild to moderate coronavirus.。

Pfizer's product is known as a "protease inhibitor" and has been shown in lab testing to jam up the virus' replication machinery.。

If it works in real life, it will likely only be effective at the early stages of infection.。

By the time COVID-19 progresses to severe disease, the virus has largely stopped replicating and patients suffer from an overactive immune response.。

Until now, COVID-19 therapeutics such as monoclonal antibodies and Gilead's remdesivir – authorized for use in the EU under the name Veklury – have been administered intravenously.。

Merck's molnupiravir was initially developed as an inhibitor of influenza and respiratory syncytial virus – two other important acute respiratory infections – by a team at Emory University in Atlanta, Georgia.。

Britain, which has been one of the countries hardest hit by the pandemic, announced on October 20 that it had ordered 480,000 doses of molnupiravir.。

Pfizer is carrying out two other clinical trials with its pill: among people who are not at risk of progressing to severe COVID-19, and among people close to someone with COVID-19 to see if it protects them against the illness.。

Besides Pfizer and Merck, the Swiss pharma giant Roche is also working on a COVID pill.。

China center Zhou hopes more Chinese players move abroad******

CANBERRA, Oct. 29 (Xinhua) -- Looking forward to playing in the Australian National Basketball League (NBL) soon, Chinese center Zhou Qi says he would like to see more Chinese players playing abroad.

"The chance [to play overseas] is valuable for one to improve," Zhou told Xinhua in a recent interview after arriving in Australia to begin a two-year stint with the South East Melbourne Phoenix.

Zhou, 25, made his debut with the Chinese national team in 2014. He signed with the Houston Rockets of the National Basketball Association (NBA) in 2017 and played as a center.

He returned to the Chinese Basketball Association (CBA) for the 2019-20 season where he averaged 20.7 points, 11.9 rebounds, 1.8 assists, and 2.5 blocks per game, according to statistics from the Phoenix.

Discussing the NBL, Zhou said his overall impression was one of "fierce confrontation".

"It seems that their style is slightly changing," he added. "The pace is now faster. So I have to give full play to my speed advantage so as to adapt quickly."

After signing the deal, Phoenix CEO Tommy Greer said Zhou, at 2.16 meters tall, whose skill set is something the club hasn't had before, can help the team cement their position at the top of the NBL this year.

Zhou revealed that the Phoenix outfit had given him a lot of support, including visa processing and flight coordination, which made him feel at home.

"I will try to show my best form in the new season," he said.

Zhou's goal is to improve himself as much as possible in the coming matches. Compared to his NBA experience, he believes he is likely to get more chances in Australia. "Playing in the NBL is a good opportunity to maintain and improve my form," he said.

The new season starts in December, meaning Zhou will have to get up to speed soon.

"This is not the first time I have gone overseas, so mentally I can prepare quickly," he said.

After his 14-day quarantine, Zhou will be left with only around 20 days to prepare for matches. "How to physically get ready is a big challenge."

Currently confined to a hotel in Melbourne, Zhou said he would do strength training every day inside his room and try to maintain his condition.

There had been reports that Zhou would like to return to the NBA, although the player replied that his focus is on the present. "I would like to see a steady improvement in myself, both in terms of skill and physical confrontation," he said.

As one of the key players in China's national team, Zhou said that before coming to Australia, he made it clear when negotiating his contract with the Phoenix that he must be able to return to China whenever he is needed by the national team.

"If the national team needs me, I have no hesitation in going," he said. Enditem




3.男排亚洲杯中国3-0横扫日本 时隔十年第二次夺冠


© 1996 - 彩神-Welcome 版权所有 xxxxx




传承红色基因 火箭军某部迎来一位特殊的“客人”| 甘肃百名人社局长给企业和求职者当“红娘”| 东南极冰盖或加速融化,480年后海平面将上升2到5米| 离婚率排在前面的是东北,北京上海,这是什么原因| 俄媒:俄空天军首架苏-57测试在即| 【天天资讯】运动属性增强,马自达CX-50特别版官图发布| 美国借“南海”议题大搞“环太军演”,26国海军参加,背后有何居心?| 黄晓明否认有私生子,却被曝买钻戒给叶珂| 深圳:无人机不再只是会飞的拍摄机器| 储户银行卡因"断卡行动"被冻结 银行员工:存在误伤| 沪漂小哥花15万买房车当家还因此找到女友:住2年回本| 微胖女生穿搭记住6点 身材越穿越好!| 73岁贪官获刑11年!退而不休,以“老书记”“老厅长”身份游走政商间| 三七价格降至历史低点!实探昆明中药材市场| 马斯克:特斯拉累计产电动车300万辆 上海超100万| 军     医| 张颖颖首直播被举报数次,汪小菲无心工作不断发飙| 雪域高原边防官兵过冬保障全面加强|